Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.44 |
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203308 | 0.85 | GHSR (0.41) | NPC1RAB9AMMP3MMP9ADAM17 | |
| SCHEMBL203307 | 0.85 | GHSR (0.41) | NPC1RAB9AMMP3MMP9ADAM17 | |
| SCHEMBL201385 | 0.80 | NPC1 (0.43) | NPC1RAB9AEPHX2SMN1; SMN2 | |
| SCHEMBL2693933 | 0.79 | MMP13 (0.41) | NPC1RAB9AMMP9 | |
| SCHEMBL9175859 | 0.75 | AGTR2 (0.53) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9175852 | 0.75 | AGTR2 (0.53) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL201235 | 0.73 | NPC1 (0.46) | NPC1RAB9AEPHX2SMN1; SMN2 | |
| SCHEMBL202603 | 0.72 | NPC1 (0.44) | NPC1RAB9AEPHX2SMN1; SMN2 | |
| SCHEMBL5351727 | 0.72 | MMP3 (0.73) | MMP3MMP9ADAM17MMP1 | |
| SCHEMBL5343011 | 0.72 | MMP3 (0.73) | MMP3MMP9ADAM17MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2338878-A2 | N-hydroxyamide derivatives possessing antibacterial activity | Vicuron Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| EP-1963262-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007069020-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | NAAA, HDHD5, HACL2 | NPC1 1027/4885RAB9A 940/4885MMP3 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.